Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.

O'Hara, Mark H; Messersmith, Wells; Kindler, Hedy; Zhang, Wei; Pitou, Celine; Szpurka, Anna M; Wang, Dan; Peng, Sheng-Bin; Vangerow, Burkhard; Khan, Anis A; Koneru, Mythili; Wang-Gillam, Andrea

O'Hara, Mark H; Messersmith, Wells; Kindler, Hedy; Zhang, Wei; Pitou, Celine; Szpurka, Anna M; Wang, Dan; Peng, Sheng-Bin; Vangerow, Burkhard; Khan, Anis A; Koneru, Mythili; Wang-Gillam, Andrea.

Afiliação

O'Hara MH; Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Messersmith W; Medicine-Medical Oncology, School of Medicine, University of Colorado, Denver, Colorado.
Kindler H; Gastrointestinal Oncology, The University of Chicago Medicine, Chicago, Illinois.
Zhang W; Eli Lilly and Company, Indianapolis, Indiana.
Pitou C; Eli Lilly and Company, Windlesham, United Kingdom.
Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana.
Wang D; Formerly with Eli Lilly and Company, Indianapolis, Indiana.
Peng SB; Eli Lilly and Company, Indianapolis, Indiana.
Vangerow B; Eli Lilly and Company, Indianapolis, Indiana.
Khan AA; AstraZeneca, Gaithersburg, Maryland.
Koneru M; Formerly with Eli Lilly and Company, Indianapolis, Indiana.
Wang-Gillam A; Department of Medicine, Molecular Oncology, Washington University School of Medicine, Washington University Medical School, St. Louis, Missouri.

J Pancreat Cancer ; 6(1): 21-31, 2020.

Article em En | MEDLINE | ID: mdl-32219196

Palavras-chave

CXCR4; LY2510924; durvalumab peptide antagonist; refractory solid tumor

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Pancreat Cancer Ano de publicação: 2020 Tipo de documento: Article